Table 5:
Predictors of new-onset cardiomyopathy or death at long-term follow-up
| Disease status at follow-up |
Did not progress (n = 496) |
Progressed (n = 75) |
Unadjusted | Adjusted for age and sex | Adjusted for age and sex, and risk factors* |
||||
|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | ||||
| Overall participants without cardiomyopathy at baseline visit (n = 571) | |||||||||
| Male sex | 227 (45.8) | 43 (57.3) | 1.59 (0.98-2.60) | 0.063 | 1.73 (1.05-2.85) | 0.031 | 1.89 (1.13 - 3.16) | 0.016 | |
| Age, years | 49 (42-56) | 53 (44-61) | 1.04 (1.01-1.06) | 0.004 | 1.05 (1.02-1.07) | 0.002 | 1.05 (1.02-1.08) | 0.001 | |
| T. cruzi serological test | |||||||||
| Negative | 266 (53.6) | 28 (37.3) | Reference | Reference | Reference | ||||
| Positive | 230 (46.4) | 47 (62.7) | 1.94 (1.18 - 3.20) | 0.009 | 2.25 (1.34 - 3.76) | 0.002 | 2.24 (1.33-3.77) | 0.002 | |
| Centers | MOC | 274 (55.2) | 30 (40.0) | Reference | Reference | Reference | |||
| SP | 222 (44.8) | 45 (60.0) | 1.85 (1.13 - 3.03) | 0.015 | 1.47 (0.87 - 2.48) | 0.144 | 1.47 (0.86 - 2.50) | 0.156 | |
| T. cruzi seropositive donors without cardiomyopathy at baseline visit (n = 277) | |||||||||
| (n=230) | (n=47) | ||||||||
| Male sex | 99 (43.0) | 26 (55.3) | 1.63 (0.87-3.08) | 0.125 | 1.73 (0.91-3.28) | 0.094 | 1.98 (1.02-3.84) | 0.043 | |
| Age, years | 48 (41-56) | 50 (41-59) | 1.02 (0.99-1.05) | 0.257 | 1.02 (0.99-1.05) | 0.185 | 1.03 (0.99-1.06) | 0.153 | |
| Benznidazole use† | 23 (10.0) | 5 (10.6) | 1.07 (0.38-2.98) | 0.895 | 1.26 (0.44-3.58) | 0.664 | 1.51 (0.48-4.69) | 0.480 | |
| T. cruzi DNA detected by PCR | |||||||||
| Negative | 129 (56.1) | 23 (48.9) | Reference | Reference | Reference | ||||
| Positive | 101 (43.9) | 24 (51.1) | 1.34 (0.71-2.51) | 0.367 | 1.32 (0.70-2.49) | 0.387 | 1.42 (0.74- 2.69) | 0.291 | |
| Centers | MOC | 123 (53.5) | 23 (48.9) | Reference | Reference | Reference | |||
| SP | 107 (46.5) | 24 (51.1) | 1.20 (0.64 - 2.25) | 0.570 | 0.98 (0.50-1.91) | 0.955 | 0.96 (0.49-1.89) | 0.916 | |
| Antibody against T. cruzi | |||||||||
| EIA (S/C) | 6.1 (4.8-6.8) | 6.5 (5.2-7.3) | 1.34 (1.06-1.70) | 0.015 | 1.38 (1.08-1.77) | 0.010 | 1.37 (1.07-1.76) | 0.011 | |
| Antibody EIA quartiles | 1st | 72 (31.3) | 10 (21.3) | Reference | Reference | Reference | |||
| 2nd | 60 (26.1) | 12 (25.5) | 1.44 (0.58-3.57) | 0.430 | 1.41 (0.56-3.53) | 0.464 | 1.39 (0.55-3.47) | 0.486 | |
| 3rd | 58 (25.2) | 9 (19.1) | 1.12 (0.43-2.93) | 0.822 | 1.16 (0.44-3.06) | 0.770 | 1.11 (0.42-2.96) | 0.829 | |
| 4th | 40 (17.4) | 16 (34.0) | 2.88 (1.20-6.94) | 0.018 | 3.23 (1.31-7.94) | 0.011 | 3.18 (1.29-7.85) | 0.012 | |
Data are expressed as the absolute numbers (percentage) or median (interquartile range-IQR)
*
Risk factors: Diabetes, hypertension, dyslipidemia, and body mass index. S/C: absorbance/cut off
†
Benznidazole was the antitrypanosomal medication
Abbreviations: MOC: Montes Claros; SP: São Paulo